Johnson & Johnson announced positive 30-day results from its FORWARD CAD study for the investigational Shockwave Javelin catheter, showing high technical success and low major cardiovascular events. This news is moderately positive for J&J as it signals progress in its medical device pipeline, potentially expanding its market share in interventional cardiology.
Johnson & Johnson reported positive 30-day results from its FORWARD CAD study for the Shockwave Javelin catheter, an investigational device designed to treat severely narrowed coronary arteries. The study showed a 93.6% technical success rate and 93.4% freedom from major cardiovascular events, indicating strong initial performance. This is significant for J&J as it validates the potential of a new product in its medical device portfolio, particularly in the lucrative interventional cardiology market. While the device is still investigational in the U.S. and the study lacked a comparison group, these early positive results could pave the way for future regulatory approvals and market entry. For traders, this represents a long-term opportunity for JNJ as it strengthens its pipeline and competitive position, though short-term impact may be limited given the investigational status.